Eplerenone is a medicine used to help lower high blood pressure and manage heart failure. It works by blocking a hormone that causes the body to retain salt and water, which helps reduce pressure on the heart and blood vessels.
Every report comes from a Lived member, sent anonymously.
Have you tried Inspra (Eplerenone) for Hyperaldosteronism?
Eplerenone, sold under the brand name Inspra and as a generic, is a prescription tablet that blocks the hormone aldosterone. It has two approved uses in adults. The first is for people who have had a heart attack and developed heart failure with reduced ejection fraction, meaning the heart's main pumping chamber squeezes out 40% or less of its blood with each beat. In that group, adding eplerenone to standard treatment helps people live longer. The second is high blood pressure, where it can be used on its own or alongside other blood pressure medicines. Doctors also use eplerenone more broadly in long-term heart failure with reduced ejection fraction, where heart failure guidelines recommend it or the related drug spironolactone (Aldactone), an older aldosterone blocker, because they lower the risk of death and hospital stays. It is also one option for primary aldosteronism, a condition in which the adrenal glands make too much aldosterone. Spironolactone is usually tried first because it is cheaper and widely available, but eplerenone is more selective and less likely to cause hormone-related side effects such as breast enlargement in men, so it is often chosen when spironolactone is poorly tolerated.
Aldosterone is a hormone made by the adrenal glands. It signals the kidneys to hold on to sodium and water and to get rid of potassium, which raises blood pressure. In heart failure, persistently high aldosterone also adds to fluid buildup and to harmful changes in the heart and blood vessels over time. Eplerenone attaches to the receptor that aldosterone normally uses (the mineralocorticoid receptor) and blocks its message. The kidneys then release more sodium and water, and blood pressure falls. The same action makes the body keep more potassium, which is why potassium levels are the main thing to watch while taking it. Compared with spironolactone, eplerenone acts much more selectively on this receptor and has little effect on sex-hormone receptors.
Eplerenone is a tablet taken by mouth, once or twice a day. After a heart attack with heart failure, it is usually started at 25 mg once a day and raised to 50 mg once a day, ideally within about four weeks, as long as potassium levels allow. For high blood pressure, the usual starting dose is 50 mg once a day, which can be increased to 50 mg twice a day. Higher doses do not lower blood pressure further and raise the risk of high potassium. People taking certain other medicines (see Interactions & Warnings) are kept on a lower dose. Blood tests are part of treatment. Potassium is checked before the first dose, within the first week, and about a month after starting or changing the dose, then periodically after that. Potassium is reported in mEq/L (milliequivalents per liter). In heart failure after a heart attack, the dose is only increased while potassium stays below 5.0; a level of 5.5 or higher usually means the dose is lowered, and 6.0 or higher means pausing the medicine until it comes back below 5.5. Kidney function is checked as well, because the kidneys are what clear potassium from the body.
Most people take eplerenone without noticeable side effects. In blood pressure studies, overall side effect rates were close to those with a placebo. Dizziness and headache are among the more common complaints and the most common reasons people stopped it in blood pressure studies. Less commonly, men can develop breast enlargement or tenderness, and women can have unusual vaginal bleeding; these are less frequent than with spironolactone. The most important side effect, high blood potassium (hyperkalemia), usually shows up on a blood test rather than as a symptom. Potassium that climbs too high can cause dangerous heart rhythm problems, which is why the tests matter and why a racing or irregular heartbeat should be reported. A rise in creatinine, a blood marker of kidney function, can also appear on tests. Contact the prescriber promptly for a rapid or irregular heartbeat, new dizziness, vomiting or diarrhea (which can upset potassium and fluid balance), new swelling in the legs, or difficulty breathing. Rarely, eplerenone can cause angioedema; swelling of the face, lips, tongue or throat needs emergency care.
Because eplerenone makes the body hold on to potassium, anything else that raises potassium adds to the risk. Do not use potassium supplements or salt substitutes that contain potassium unless the prescriber agrees. The risk of high potassium is also greater for people with reduced kidney function, diabetes or protein in the urine, and for those also taking an ACE (angiotensin-converting enzyme) inhibitor such as lisinopril or an ARB (angiotensin receptor blocker) such as losartan. Those two combinations are often used deliberately in heart failure, so the answer is closer blood test monitoring rather than automatically avoiding them. NSAID (nonsteroidal anti-inflammatory drug) pain relievers such as ibuprofen or naproxen are different: they also raise potassium with eplerenone, and in heart failure they cause the body to hold on to salt and fluid and can strain the kidneys, so they are best avoided or used only after checking with the prescriber. The liver breaks down eplerenone using an enzyme called CYP3A. Medicines that strongly block this enzyme, including the antifungals ketoconazole and itraconazole, the antibiotic clarithromycin, and the HIV medicines ritonavir and nelfinavir, can raise eplerenone to unsafe levels and must not be taken with it. Moderate blockers, such as erythromycin, fluconazole and the heart medicine verapamil, call for a lower eplerenone dose. Eplerenone can also raise lithium levels, so lithium is checked more often if the two are combined. Eplerenone is not started if potassium is already above 5.5 mEq/L or kidney function is severely reduced (creatinine clearance, an estimate of how well the kidneys filter blood, of 30 mL per minute or less). When it is prescribed only for high blood pressure, it is also avoided in people with moderately reduced kidney function, in type 2 diabetes with protein leaking into the urine, and alongside potassium supplements or other potassium-sparing diuretics such as spironolactone, amiloride or triamterene. Information on use during pregnancy and breastfeeding is limited, so anyone pregnant, planning pregnancy or breastfeeding should discuss it with the prescriber.
For high blood pressure, readings usually start to come down within two weeks, with the full effect by about four weeks. It is often one of two or more blood pressure medicines rather than the only one. After a heart attack or in heart failure, the benefit is not something a person feels day to day: it shows up as a lower chance of dying or being admitted to hospital over months and years. In the main post-heart-attack trial, people taking eplerenone with standard treatment had about 15% fewer deaths over roughly 16 months than those taking a placebo. The first weeks involve the most blood tests while the dose is set; after that, checks become periodic, with extra tests after a dose change, a new interacting medicine, dehydration from vomiting or diarrhea, or a change in kidney function. For heart failure, eplerenone is usually a long-term treatment, and stopping it means losing its protective effect, so changes should be planned with the prescriber.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Inspra (Eplerenone), what you've noticed, or ask the community a question.